Recently, Zimbabwe has begun rolling out lenacapavir, a long-acting injectable HIV prevention medicine.
About Lenacapavir:
It is the new long-acting injectable HIV-prevention drug.
It is the first twice-yearly injectable pre-exposure prophylaxis (PrEP) for HIV, offering a highly effective, long-acting alternative to daily oral pills.
PrEP is a medication that can reduce the risk of HIV infection for individuals who are HIV-negative but are at risk of contracting the virus.
The results of two key studies have shown that it helps prevent 99.9 per cent of all HIV transmission.
It is developed by Gilead Sciences and marketed under the brand name Yeztugo.
How does lenacapavir work?
Lenacapavir is a capsid inhibitor, a class of drugs that blocks the protein shell (capsid) the HIV virus needs to replicate.
Unlike oral PrEP pills that must be taken daily, lenacapavir is administered as an injection once every six months, providing a discreet and highly effective method of prevention.
Dear Student,
You have still not entered your mailing address. Please enter the address where all the study materials will be sent to you. (If applicable).
